We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment with Simvastatin in Patients with Alzheimer's Disease Lowers Both α and β-Cleaved Amyloid Precursor Protein.
- Authors
Sjögren, Magnus; Gustafsson, Kina; Syversen, Steinar; Olsson, Annika; Edman, Åke; Davidsson, Pia; Wallin, Anders; Blennow, Kaj
- Abstract
We investigated the clinical and biological effects of cholesterol-lowering treatment with a statin in 19 patients with Alzheimer's disease. They received simvastatin 20 mg/day for 12 weeks in an open trial. Primary efficacy parameters were the changes after 12 weeks in the cerebrospinal fluid (CSF) levels of β-amyloid42 (Aβ42), α-secretase- cleaved amyloid precursor protein (α-sAPP), β-secretase- cleaved APP (β-sAPP), tau, phospho-tau and the plasma levels of Aβ42. A secondary efficacy parameter was the change in the Alzheimer's Disease Assessment Scale-Cognition (ADAS-cog) score. After 12 weeks, CSF α-sAPP and CSF β-sAPP were significantly reduced (p < 0.001), but the CSF levels of tau, phospho-tau, Aβ42 and the plasma levels of Aβ42 were unchanged. The ADAScog score was slightly increased (p < 0.05). The results suggest that simvastatin acts directly on the processing of APP by inhibiting both the α- and the β-secretase pathways.
- Subjects
STATINS (Cardiovascular agents); ALZHEIMER'S disease treatment; AMYLOID beta-protein; CEREBROSPINAL fluid; BIOMARKERS
- Publication
Dementia & Geriatric Cognitive Disorders, 2003, Vol 16, Issue 1, p25
- ISSN
1420-8008
- Publication type
Article
- DOI
10.1159/000069989